Fabry disease is a rare genetic disease started by a faulty gene i.e., the Galactosidase Alpha DNA in the body. The imperfection in the gene leads to a shortage of the enzyme alpha-galactosidase A. This enzyme is important for the daily breakdown of a fatty materials in the body known globotriaosylceramide. When correct break of this lipid and other same lipids does not take place, GL-3 gathers in the mainstream of cells from the body which causes damage to cells. The cell damage is a source for a vast range of signs comprising strongly life-threatening results such as renal outbreak or cardiac failure.
LATAM fabry disease market is evaluated to be estimated at US$ 81.330 Mn in 2022 and is anticipated to show a CAGR of 6.7% during the predicted duration (2022-2030)
Request Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/5249
• Prodromes of fabry disease comprise severe pain through physical activity, thermal or cold intolerance, swelling or pain in the hands or legs, faintness, loss in hearing or ringing in ears, bulging in the legs, ankles or feet, etc.
• Analysis to cure fabry disease comprises Enzyme assay, Genetic trials, Newborn screenings, etc.
• Fabry disease is cured by treatments such as ERT, CT, Gene Therapy, SRT, etc.
Impact of the Coronavirus
The COVID-19 outbreak is predicted to hinder growth of the LATAM fabry disease market, due to adverse effect on supply chain through the COVID-19 epidemic. For example, as per data reported by UN Office on Drugs and Crime, there was effect of the actions executed to regulate the spread of the corona virus on drug supply chain, in the destination markets. Several regions have stated a complete lack of various kinds of medicines at the retail level. The corona virus constraint had limited the supply of medicines in market, at retail level.
Rising price of the drugs through COVID-19 epidemic might have an adverse effect on growth of the fabry disease market in Latin America. For example, as per data reported by UNO on Drugs and Crime, total lockdown was executed in several regions globally through COVID-19 pandemic which led into disorder in the transport of medicine from one region to other, which has led to increased cost of the medicines worldwide which is anticipated to impede growth of the LATAM fabry disease market.
Driver:
Growth of consensus documents for fabry disease by hospital community is anticipated to fuel the market growth of the LATAM fabry disease market, during the predicted duration. For example, as per data generated in June, 2022 by BJN, Committee for Rare Diseases – BSN, developed a consensus document to normalize recommendations associated to renal involvement in fabry disease in the fields of diagnosis, monitoring, and therapy of adult and pediatric sufferers. The growth of the consensus statement targets to help doctors and sufferers about the outcomes of the therapy for fabry disease.
Rising R&D for drug development by key companies present in Latin America is predicted to fuel growth of the LATAM fabry disease market, during the predicted duration. For example, on October 23, 2019, Amicus Therapeutics, a biotechnology company, effectively finished a Phase III medical trial for fabry disorder. The survey was performed to calculate the long-term security and efficiency of Migalastat Hydrochloride Monotherapy in sufferers with fabry disorders. The survey reported 0.00% fatality of the sufferers who contributed in clinical tests and pver 30.95% patients have been stated with negative impacts.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/5249
Lack of proper treatment for fabry disease in countries of Latin America is expected to hinder growth of the LATAM fabry disease market, during the predicted duration. For example, as per an article generated on February 10, 2021, by NCBI, Brazil is at the threat for the accessibility of the therapy such as enzyme replacement treatment, for the patiens with Fabry disease. Brazil is one of the populated region in Latin America and shortage of proper therapy for the sufferers with fabry disease is anticipated to hinder growth of the LATAM fabry disease market.
Country Analysis
Regionally, the LATAM fabry disease market is divided into Argentina, Brazil, Mexico, and Rest of Latin America.
Amongst Region, Argentina fabry disease market is anticipated to reatin a leading place over the predicted duration, due to rising cases of sufferers with fabry disease. For example, as per an article reported on March, 2018, by NCBI, A team of scientists assessed the frequency of fabry disease in Argentina of young adults who had attack and published that 3% of patients were detected with fabry disorder.
Furthermore, Brazil is also expected to witness notable growth in the LATAM fabry disease market, due to rising R&D by research institutes in partnership with key market players. For example, as per the source clinicaltrials.gov University of Sao Paulo General Hospital in partnership with Pfizer Inc., on September 9, 2020 had introduced medical tests for Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique in sufferers With Amyloidosis and Fabry Disease to calculate the diastolic myocardial elasticity in sufferers with Fabry disease and relate it to the transthyretin amyloidosis class with cardiac involvement.
Competitive Landscape
Key players involved in the LATAM fabry disease market are Teva pharmaceutical Industries Ltd, Amicus Therapeutics, Inc., Pfizer Inc., Moderna Therapeutics Inc, Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Takeda Pharmaceuticals U.S.A., Inc,, Mendelics, Novartis AG, and Resverlogix.
Reasons to buy this LATAM Fabry Disease Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ LATAM Fabry Disease market size estimation and recent advancements in the industry are explained.
Buy Now This Premium Report to Grow your Business @
https://www.coherentmarketinsights.com/insight/buy-now/5249
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Recent Product Launch/Approval
- Key Strategies Adopted by Market Players
- PEST Analysis
- Epidemiology
- Mergers and Acquisitions
- Market Dynamics
- LATAM Fabry Disease Market – Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Supply Chain
- Government Initiatives
- LATAM Fabry Disease Market, By Therapy Type, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Enzyme Replacement Therapy
- Agalsidase Beta (Fabrazyme)
- Agalsidase Alfa (Replagal)
- Pegunigalsidase Alfa (PRX-102, Phase III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Chaperon Therapy
- Migalastat (Galafold Phase III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Migalastat (Galafold Phase III)
- Enzyme Replacement Therapy
- Lucerastat (Phase III)
- Venglustat (Phase III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- LATAM Fabry Disease Market, By Route of Administration, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- LATAM Fabry Disease Market, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- LATAM Fabry Disease Market, By Country, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Country, 2017–2030
- Latin America
- Brazil
- Market Size and Forecast, By Therapy Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Mexico
- Market Size and Forecast, By Therapy Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Argentina
- Market Size and Forecast, By Therapy Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Rest of Latin America
- Market Size and Forecast, By Therapy Type, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Brazil
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Amicus Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi-Aventis U.S. LLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mendelics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceuticals U.S.A., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Moderna Therapeutics Inc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Resverlogix
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amicus Therapeutics, Inc.
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837